Clinical trials: Physical activity
Relapsing-remitting Multiple Sclerosis, RRMS
POC-MD MRI-based Trial in Relapsing-remitting Multiple Scler
A randomized, multi-center, double-blind, proof-of-concept study to assess the effect of multiple infusions of AIN457 (10 mg/kg) versus placebo on disease activity as measured by MRI scans over a 24 week period in patients with…
- Trial name
- NCT01051817
- Testing
- AIN457
- Where
- 16 sites in Czechia, Russia and 1 more
- Volunteers
- 73 people
- Sponsor
- Novartis Pharmaceuticals
Relapsing-Remitting Multiple Sclerosis
A Study to Assess the Effects of MK0812 on Disease Activity in Patients With Relapsing-Remitting Multiple Sclerosis as Measured by Magnetic Resonance Imaging (MRI)(0812-003)(COMPLETED)
The purpose of this study is to test MK0812 on disease activity in patients with relapsing-remitting MS. Disease modifying activity will be assessed by measurement of brain lesions via MRI brain scans and an open label extension…
- Trial name
- NCT00239655
- Testing
- MK0812
- Volunteers
- 120 people
- Sponsor
- Merck Sharp & Dohme LLC
Metastasis, Neoplasm
A Phase 1 Study of BPI-28592 in Subjects With Advanced Solid Tumors
This is an open-labe Phase I study of BPI-28592 for the treatment of patients with solid tumors
- Trial name
- NCT05302843
- Testing
- BPI-28592
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
Alzheimer Disease (AD)
A Study Evaluating the Efficiency and Safety for the VGuard Device in Alzheimer's Disease.
The project will allow the assessment of the safety and clinical effectiveness of the device for the treatment of cognitive impairment at Alzheimer\'s diease.
- Trial name
- CogniGuard (NCT06620640)
- Testing
- Intervention will most probably modify activity of neuron networks in specific brain areas responsible for cognitive functions, especially memory consolidation.
- Where
- Poland
- Volunteers
- 105 people
- Sponsor
- Neuromedical Sp. z o.o.
Advanced Solid Tumors, Colorectal Cancer
A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Patients With Advanced Solid Tumors
This is a Phase Ib study that will evaluate the Safety, Tolerability , Pharmacokinetics, Activity and Immunogenicity of HS-10370 in Combination With Other Anti-cancer Therapies in Chinese patients with KRAS G12C mutation advanced…
- Conditions
- Advanced Solid Tumors, Colorectal Cancer, Non-Small Cell Lung Cancer
- Trial name
- NCT06963502
- Testing
- HS-10370, HS-20117, Adebrelimab
- Where
- 2 sites in China
- Volunteers
- 762 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Polypoid Choroidal Vasculopathy (PCV)
Phase IV Clinical Trial (STAR Study) Extension Study of Conbercept Ophthalmic Injection for Treatment of Polypoid Choroidal Vasculopathy
To explore efficacy and safety of 0.5 mg conbercept ophthalmic injection for long-term treatment of polypoid choroidal vasculopathy (PCV) subjects.
- Trial name
- NCT03244657
- Testing
- conbercept ophthalmic injection （0.5mg）
- Where
- 30 sites in China
- Volunteers
- 200 people
- Sponsor
- Chengdu Kanghong Biotech Co., Ltd.
HIV Infections
Study to Determine the Antiviral Activity and Safety of Alovudine in Nucleoside-experienced HIV-infected Subjects Experiencing Virologic Failure
The primary objective was to determine the mean change in HIV viral load from baseline to Week 4 compared with placebo after 4 weeks of treatment in highly experienced HIV-infected patients.
- Trial name
- NCT02232581
- Testing
- Alovudine - low, Alovudine - medium, Alovudine - high
- Volunteers
- 72 people
- Sponsor
- Boehringer Ingelheim
Chronic Inducible Urticaria
A Dose Escalation Trial of Safety, Pharmacokinetic/Pharmacodynamic and Preliminary Clinical Activity of Briquilimab in Adult Patients With Chronic Inducible Urticaria (CIndU) Who Remain Symptomatic Despite Treatment With H1- Antihistamines
This is an open-label, single ascending dose Phase 1b/2a trial to determine the safety and tolerability and assess the preliminary efficacy of briquilimab in adult participants with Cold Urticaria (ColdU) or Symptomatic…
- Trial name
- SPOTLIGHT (NCT06353971)
- Testing
- Briquilimab
- Where
- 5 sites in Germany
- Volunteers
- 27 people
- Sponsor
- Jasper Therapeutics, Inc.
Immunity to COVID-19
Immunity After COVID-19 Vaccination
The purpose of the research is to evaluate new blood tests, which measure immunity to the COVID-19 coronavirus after vaccination. These tests will be used to measure T-cell and antibody immunity after COVID-19 vaccination.
- Trial name
- NCT04883164
- Testing
- Cellular and antibody response to spike antigens of SARS-CoV-2 in both groups in peripheral blood samples
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Plexision
Metastatic Castration Resistant Prostate Cancer
Trial of LAVA-1207 in Patients With Therapy Refractory Metastatic Castration Resistant Prostate Cancer (mCRPC) Resistant Prostate Cancer
This is a phase 1, first-in-human study to evaluate Safety, Tolerability, PK, PD, Immunogenicity, and Antitumor Activity of LAVA-1207 alone or with low dose interleukin-2 or Pembrolizumab, in patients with therapy refractory…
- Trial name
- NCT05369000
- Testing
- LAVA-1207, LAVA-1207 plus Pembrolizumab
- Where
- 12 sites in United States, Netherlands and 1 more
- Volunteers
- 96 people
- Sponsor
- Lava Therapeutics
TTR-mediated Amyloidosis
Phase 2 Study to Evaluate ALN-TTRSC (Revusiran) in Patients With Transthyretin (TTR) Cardiac Amyloidosis
The purpose of this study is to determine the pharmacokinetics, pharmacodynamics and exploratory clinical activity of ALN-TTRSC (revusiran) in Patients with Transthyretin (TTR) Cardiac Amyloidosis.
- Trial name
- NCT01981837
- Testing
- ALN-TTRSC (revusiran) for subcutaneous administration
- Where
- 4 sites in United States, United Kingdom
- Volunteers
- 26 people
- Sponsor
- Alnylam Pharmaceuticals
Hemophilia A, Severe
A Study Evaluating Physical Activity and Joint Health in Severe Haemophilia A Patients ≥12 Years Treated Once Weekly With Efanesoctocog Alfa
FREEDOM is a multicentre, open-label, single-arm, phase 3b study in Europe that aims to enrol approximately 90 previously treated severe haemophilia A patients aged ≥12 years, currently on prophylaxis.
- Trial name
- FREEDOM (NCT05817812)
- Testing
- Efanesoctocog alfa
- Where
- 30 sites in Austria, Croatia and 12 more
- Volunteers
- 93 people
- Sponsor
- Swedish Orphan Biovitrum
Solid Tumors
Phase I Study of BAY1436032 in IDH1-mutant Advanced Solid Tumors
The primary objective of this study is: Determine the safety, tolerability, maximum tolerated dose (MTD) or recommended Phase II dose (RP2D) of BAY 1436032 in patients with isocitrate dehydrogenase-1 (IDH1)-R132X-mutant advanced…
- Trial name
- NCT02746081
- Testing
- BAY1436032
- Where
- 13 sites in United States, Denmark and 2 more
- Volunteers
- 81 people
- Sponsor
- Bayer
Diabetes, Diabetes Mellitus, Type 2
Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Diet and Exercise Only
This trial is conducted globally. The aim of this trial is to investigate efficacy and safety of oral semaglutide versus placebo in subjects with type 2 diabetes mellitus treated with diet and exercise only.
- Trial name
- PIONEER 1 (NCT02906930)
- Testing
- semaglutide
- Where
- 105 sites in United States, Algeria and 9 more
- Volunteers
- 703 people
- Sponsor
- Novo Nordisk A/S
Lymphoma
A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Oral Tomivosertib (eFT-508) in Subjects With Hematological Malignancies
This clinical trial is a Phase 1-2, open-label, sequential-group, dose-escalation and cohort-expansion study evaluating the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of Tomivosertib (eFT-508).
- Trial name
- NCT02937675
- Testing
- Tomivosertib (eFT-508)
- Where
- 10 sites in United States
- Volunteers
- 28 people
- Sponsor
- Effector Therapeutics
Alopecia Areata, Vitiligo
A Study of DR-01 in Subjects With Alopecia Areata and Vitiligo
This is a multi-center, parallel-group, open-label, randomized, Phase 1b study to explore the safety, clinical activity, pharmacokinetics and pharmacodynamics of DR-01 in adults with Alopecia Areata or Vitiligo.
- Trial name
- NCT06602232
- Testing
- DR-01
- Where
- 20 sites in United States, Australia and 1 more
- Volunteers
- 81 people
- Sponsor
- Dren Bio
Acute Postoperative Pain, Chest Wall Surgery
Prospective Feasibility, Analgesic Effectiveness, and Safety Study of a Visual Analog Scale-Guided Multimodal Pain Algorithm After Posterior Rib Remodeling With Osteosynthesis
This prospective single-group study will evaluate a visual analog scale-guided multimodal analgesia algorithm during the first five days after posterior rib remodeling with osteosynthesis.
- Trial name
- NCT07805928
- Testing
- VAS-Guided Multimodal Analgesia Algorithm, Ultrasound-Guided Thoracic Wall Regional Block
- Where
- Colombia
- Volunteers
- 160 people
- Sponsor
- Research Inc
Parkinson Disease
Pilot Study to Evaluate the Self-Management of Gait, Speech, and Dexterity Symptoms in Parkinson's Disease Using a Smartphone Application
The purpose of this study is to evaluate the impact of a smartphone application that delivers at-home therapy exercises on patients' self-management of gait, speech, and dexterity symptoms.
- Trial name
- NCT05120609
- Testing
- Parkinson's Application
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Beats Medical
Systemic Lupus Erythematosus, Rheumatoid Arthritis
Electromagnetic Immunotherapy Mapping and Cytokine Forecasting Study (QSIT)
The ImmuneNet study is a Phase I/II clinical trial sponsored by Truway Health, Inc. It will test whether gentle, low-frequency electromagnetic resonance (LF-EMR) can influence how immune cells communicate and synchronize with…
- Conditions
- Systemic Lupus Erythematosus, Rheumatoid Arthritis, Multiple Sclerosis, Autoimmune Diseases
- Trial name
- QSIT (NCT07221565)
- Testing
- Low-Frequency Electromagnetic Resonance Therapy (LF-EMR), Low-Dose Naltrexone (LDN)
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Truway Health, Inc.
Shoulder Pain
Assessment of Rural Health Care: Implementing TRAK Digital Tool for Quality and Accessible Services
This clinical trial aims to analyze the usability and degree of satisfaction of two populations, healthcare personnel (Population 1) in rural areas and their patients (Population 2), with the TRAK tele-rehabilitation tool.
- Trial name
- TRAK-RURAL (NCT06796309)
- Testing
- Trak Telerehabilitation Platform, Conventional Rehabilitation Program
- Where
- Spain
- Volunteers
- 95 people
- Sponsor
- Trak Health Solutions S.L.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.